share_log

Tonix Pharmaceuticals Publishes Peer-Reviewed Publication In MSphere Journal Highlighting Tolerability Of Its Single-Dose Mpox And Smallpox Vaccine Candidate TNX-801, In Immune-Compromised Animals

Tonix Pharmaceuticals Publishes Peer-Reviewed Publication In MSphere Journal Highlighting Tolerability Of Its Single-Dose Mpox And Smallpox Vaccine Candidate TNX-801, In Immune-Compromised Animals

tonix pharmaceuticals發表了在《MSphere Journal》中發表的經同行評議的論文,重點介紹了其單劑量Mpox和天花疫苗候選藥TNX-801在免疫受損動物中的耐受性。
Benzinga ·  11/13 22:07

The World Health Organization (WHO) declared the spread of new Clade Ib Mpox a public health emergency of international concern (PHEIC): Second Mpox-related WHO PHEIC declaration in two years

世界衛生組織(WHO)將新克萊德Ib Mpox的傳播宣佈爲國際關注的公共衛生緊急事件(PHEIC):這是兩年來第二次與Mpox相關的WHO PHEIC聲明

Clade Ib Mpox cases detected in 16 African countries and outside of Africa, in Sweden, Thailand, Singapore, India, Germany and England

在16個非洲國家以及瑞典、泰國、新加坡、印度、德國和英國發現了克萊德Ib Mpox病例

Single-dose mpox vaccines with durable protection may be required to address global health emergency

可能需要單劑量的mpox疫苗以提供持久的保護,來應對全球健康緊急事件

TNX-801 was shown to be more than 10- to 1,000-fold more attenuated (or less virulent) compared to the older vaccinia smallpox vaccines: Tolerability of TNX‐801 vaccination in immune-compromised animal models supports clinical development

與舊的水痘疫苗相比,TNX-801的減毒超過了10到1,000倍(或致病性更低):TNX-801在免疫受損動物模型中的耐受性支持了其臨床開發

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論